secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2024-03-29T23:59:59+00:00
Accession:  0001104659-24-041158
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis Precision Medicines prices $56.50/share offering, expected $215.6M net proceeds
--------------------------------------------------------------------------------

- Offering includes 3,318,585 shares at $56.50 and 221,238 pre-funded warrants at $56.4999; underwriters exercised option for 530,973 additional shares.
- Net proceeds of ~$215.6M after discounts and expenses; closing expected April 2, 2024.
- Proceeds to accelerate PRAX-628 development and continue R&D for ulixacaltamide, PRAX-562, and PRAX-222.
- Company believes existing cash plus net proceeds will fund operations into 2027.
- Underwriters: Piper Sandler, Guggenheim Securities, and Truist Securities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000110465924041158/0001104659-24-041158-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000110465924041158/tm247764d6_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-041158

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer